Comparative Pharmacology
Head-to-head clinical analysis: GEFITINIB versus QLOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEFITINIB versus QLOSI.
GEFITINIB vs QLOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; inhibits EGFR autophosphorylation and downstream signaling, leading to cell cycle arrest and apoptosis in EGFR-overexpressing tumors.
QLOSI is a monoclonal antibody that binds to and inhibits the activity of interleukin-5 (IL-5), thereby reducing eosinophil production and survival.
250 mg orally once daily
100 mg orally once daily.
None Documented
None Documented
Terminal half-life 48 hours (range 24-85 hr); supports once-daily dosing, steady state achieved by day 7-10
Clinical Note
moderateGefitinib + Digoxin
"Gefitinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGefitinib + Digitoxin
"Gefitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGefitinib + Deslanoside
"Gefitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGefitinib + Acetyldigitoxin
"Gefitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 9 hours; clinical context: allows twice-daily dosing in patients with normal renal function.
Primarily fecal (86% unchanged + metabolites), renal excretion <5%
Primarily renal excretion of unchanged drug (approximately 85%), with the remainder eliminated via biliary/fecal routes (15%).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor